Gene · 54583
EGLN1: egl-9 family hypoxia inducible factor 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. EGLN1: egl-9 family hypoxia inducible factor 1. Genes, record 54583. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/54583
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9GZT9 | Egl nine homolog 1 | 426 | 64 | Ensembl, GeneID, HGNC |
Source UniProt
Patents51
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 44805 | Q9GZT9 | Espacenet |
| EP 4663754 A2 | 2025-12-17 | 13 | Q9GZT9 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 8089 | Q9GZT9 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 8089 | Q9GZT9 | Espacenet |
| EP 4491229 A2 | 2025-01-15 | 68 | Q9GZT9 | Espacenet |
| WO 2024230934 A1 | 2024-11-14 | 193 | Q9GZT9 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 26827 | Q9GZT9 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 129798 | Q9GZT9 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 3428 | Q9GZT9 | Espacenet |
| WO 2020161342 A1 | 2020-08-13 | 68 | Q9GZT9 | Espacenet |
1 to 10 of 51
See all 51 patentsDrugs5
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| DAPRODUSTAT | CHEMBL3544988 | Hypoxia-inducible factor prolyl hydroxylase inhibitor | INHIBITOR | ChEMBL |
| ENARODUSTAT | CHEMBL4297619 | Egl nine homolog 1 inhibitor | INHIBITOR | ChEMBL |
| MOLIDUSTAT | CHEMBL3646118 | Egl nine homolog 1 inhibitor | INHIBITOR | ChEMBL |
| ROXADUSTAT | CHEMBL2338329 | Hypoxia-inducible factor prolyl hydroxylase inhibitor | INHIBITOR | ChEMBL |
| VADADUSTAT | CHEMBL3646221 | Egl nine homolog 1 inhibitor | INHIBITOR | ChEMBL |
Trials116
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07565701 | VADADUSTAT | PHASE3 | ClinicalTrials.gov | |
| NCT07548671 | ENARODUSTAT | PHASE3 | ClinicalTrials.gov | |
| NCT07537816 | VADADUSTAT | PHASE4 | ClinicalTrials.gov | |
| NCT07359027 | ROXADUSTAT | PHASE4 | ClinicalTrials.gov | |
| NCT07346547 | DAPRODUSTAT | ClinicalTrials.gov | ||
| NCT07300111 | DAPRODUSTAT | PHASE3 | ClinicalTrials.gov | |
| NCT07268807 | ROXADUSTAT | ClinicalTrials.gov | ||
| NCT07136792 | ROXADUSTAT | ClinicalTrials.gov | ||
| NCT07086755 | VADADUSTAT | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07045155 | ROXADUSTAT | PHASE4 | ClinicalTrials.gov |
1 to 10 of 116
See all 116 trialsNIH grants1,902
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | EGLN1 papers | Newest fiscal year |
|---|---|---|---|
| P01CA108671 | Myeloproliferative Neoplasms-Research Consortium | 12 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 12 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 11 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 8 | 2025 |
| P30CA060553 | The Robert H. Lurie Comprehensive Cancer Center | 7 | 2025 |
| P30CA086862 | Cancer Center Support Grant | 7 | 2025 |
| P50CA101942 | DF/HCC Kidney Cancer SPORE (supplement) | 7 | 2025 |
| ZIABC011773 | Hypoxia signaling in cancer development | 6 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 5 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 5 | 2025 |
1 to 10 of 1,902Source NIH's project files
See all 1,902 nih grantsPapers3,727
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CCN1 upregulation in diabetic wounds suppresses PINK1/Parkin-mediated mitophagy in dermal fibroblasts by regulating HIF-1α protein stability under decompensated hypoxic conditions. | Cell Signal | 2026 | 42802000 | PubTator, text mining | PubMed |
| PGC1α-mediated upregulation of PHD2 represses HIF-signaling, limiting prostate cancer progression. | Cell Death Differ | 2026 | 42754649 | PubTator, text mining | PubMed |
| Current insights into PHF14: molecular features and functional roles. | Front Mol Biosci | 2026 | 42698416 | PubTator, text mining | PubMed |
| ERN1 inhibition modifies hypoxic regulation of EGLN1 expression in U87MG glioblastoma cells. | Endocr Regul | 2026 | 42672129 | PubTator, text mining | PubMed |
| Plant-Based α-Linolenic Acid as a Superior Nutraceutical to Modulates Apoptosis, Hypoxic Signaling, and Lipid Metabolic Pathway in Breast Cancer: A Comparative Preclinical Study. | Mol Nutr Food Res | 2026 | 42671985 | PubTator, text mining | PubMed |
| Genetic Modifiers of Cardiac Remodeling Severity in IVS4+919G>A-Associated Fabry Cardiomyopathy. | Int J Mol Sci | 2026 | 42653448 | PubTator, text mining | PubMed |
| Development of endothelial injury under chemical hypoxia: early migration impairment precedes cytotoxicity in CoCl2-treated EA.hy926 cells. | Mol Biol Rep | 2026 | 42631778 | PubTator, text mining | PubMed |
| Fluoride induced chondrocyte extracellular matrix degradation by inhibition of glycolysis by the PHD2/HIF1α signaling pathway. | Environ Toxicol Pharmacol | 2026 | 42628705 | PubTator, text mining | PubMed |
Methylglyoxal Attenuates Mycobacterium avium subspecies paratuberculosis (MAP)-Induced Pro-Inflammatory Macrophage Programming Associated with NRF-2 Antioxidant Responses and Reduced MCT4/Lactate-Linked Inflammatory Markers. | Int J Mol Sci | 2026 | 42589594 | PubTator, text mining | PubMed |
| Familial erythrocytosis associated with an EGLN1 (PHD2) variant of uncertain significance with emerging evidence of pathogenicity. | BMJ Case Rep | 2026 | 42586595 | PubTator, text mining | PubMed |
1 to 10 of 3,727
See all 3,727 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/54583
GET https://conductscience.org/api/genes/v1/54583/patents?page=2